For its second fiscal quarter (ending June 30), Cytokinetics Inc (NASDAQ: CYTK) has reported E.P.S. of $-1.31 compared to $-1.34 a year ago. Relative to the consensus estimate of $-0.91, this was a shortfall of $-0.40. For the latest four quarters through June 30, E.P.S. were $-5.37 versus $-5.69 for the same period a year ago.
Recent Price Action
On 8/8/24, Cytokinetics Inc (NASDAQ: CYTK) stock enjoyed a very large increase of 5.4%, closing at $54.00. Trading volume in this advance was normal. The stock has been strong relative to the market over the last nine months but has declined -8.5% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, CYTK is expected to be a major Value Eraser.
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment